Cytek Biosciences Inc. (CTKB) exhibits 51.8% gross margins and -12.7% return on invested capital within Health Care (Biotechnology: Laboratory Analytical Instruments), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 51.8% gross profitability converts into -20.0% operating margin and -12.7% ROIC, outpacing sector cost of capital.
ROIC: -12.7% // GM: 51.8%YoY revenue trajectory of +0.5% paired with -1.07% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +0.5% // FCF YLD: -1.07%Altman Z-Score of 4.76 and Piotroski F-Score of 3/9 indicate low near-term refinancing stress.
ALTMAN Z: 4.76 // F-SCORE: 3/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $6.30 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Laboratory Analytical Instruments require continuous execution to defend -33.0% net margins.
NET MARGIN: -33.0% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for CTKB & activate live FRED threshold breach alerts.